Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Cash & Equivalents (2016 - 2025)

Anaptysbio (ANAB) has disclosed Cash & Equivalents for 10 consecutive years, with $238.2 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents rose 93.53% year-over-year to $238.2 million, compared with a TTM value of $238.2 million through Dec 2025, up 93.53%, and an annual FY2025 reading of $238.2 million, up 93.53% over the prior year.
  • Cash & Equivalents was $238.2 million for Q4 2025 at Anaptysbio, up from $109.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $495.7 million in Q4 2021 and bottomed at $26.3 million in Q3 2023.
  • Average Cash & Equivalents over 5 years is $147.0 million, with a median of $96.6 million recorded in 2023.
  • The sharpest move saw Cash & Equivalents plummeted 85.62% in 2022, then surged 628.58% in 2024.
  • Year by year, Cash & Equivalents stood at $495.7 million in 2021, then tumbled by 85.62% to $71.3 million in 2022, then tumbled by 49.56% to $36.0 million in 2023, then soared by 242.22% to $123.1 million in 2024, then soared by 93.53% to $238.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for ANAB at $238.2 million in Q4 2025, $109.8 million in Q3 2025, and $44.3 million in Q2 2025.